Teladoc Health, Inc.
Here’s whether Teladoc Health, Inc. (TDOC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); 3-month momentum positive (+7.1%). Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.48% over 10 days); RSI 30 — oversold. Currently 31.1% off its 52-week high. Score: +0/7.
TDOC is holding above its long-term 200-day MA ($6.79) but has slipped below the 50-day MA ($8.09), pointing to short-term weakness in an otherwise intact trend. An RSI of 29.6 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -6.7% compares to +20.4% for SPY (trailed the market by 27.1%). The current 31.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.